CAR-T Therapy Revolutionizing Cancer Treatment
The Human Genome Project’s completion in 2003 paved the way for personalized medicines tailored to individual patients.
One groundbreaking example is CAR-T therapy, an innovative immunotherapy that reprograms a patient’s own T-cells to target and destroy cancer cells.
In this process, researchers extract T-cells, modify them in a lab to produce chimeric antigen receptors (CARs) and then reintroduce these CARs into the patient to actively target and eradicate cancer. Researchers are currently developing nearly 800 CAR-T therapies, with a focus on enhancing efficacy, improving safety and streamlining manufacturing to further transform cancer care.

Our Work in Action
With the support of a unique ecosystem and policy environment that foster transformative advancements, this progress positions America as the global leader in biopharmaceutical innovation.